Starting Wegovy: what day-one TikTok posts get right and wrong

What did @allisonmckoy actually say?

Allison is starting what she calls "the Wegovy tablet" at a starting weight of 179 pounds, with a goal of reaching 140-150 pounds. She mentions feeling nauseous on day one and wonders aloud whether it's psychosomatic, saying she doesn't know "if it's in my head." She's also struggling with hydration and has pre-existing anxiety around nausea and vomiting.

That's actually a pretty honest, low-key intro. She's not promising miracle results or pushing a product. The main thing worth examining here is whether a "Wegovy tablet" is even the right way to describe what she's taking, because that framing could genuinely confuse people watching.

Does the science back this up?

Here's the thing: Wegovy, as FDA-approved, is a subcutaneous injection, not a tablet. There is an oral semaglutide product on the market called Rybelsus, but it's approved for type 2 diabetes management, not weight loss. So if Allison is taking an oral pill she's calling "Wegovy," that's either a branding misunderstanding or she may be taking a compounded oral semaglutide formulation, which is a very different product.

The OASIS 1 trial (Knop et al., 2023, NEJM) tested a high-dose oral semaglutide formulation (50mg) for obesity and found about 15.1% body weight reduction over 68 weeks. That's promising, but this formulation is not the same as Rybelsus and is not yet broadly FDA-approved for weight loss as a commercial product. Meanwhile, the injectable Wegovy (2.4mg semaglutide) showed 14.9% weight loss in the STEP 1 trial (Wilding et al., 2021, NEJM). The oral and injectable routes have meaningfully different bioavailability profiles, and they are not interchangeable.

What did they get wrong (or right)?

She got a few things right, actually. Early nausea is real and well-documented with semaglutide. The STEP trials consistently reported nausea as the most common adverse event, affecting roughly 44% of participants. Her instinct that it might be anxiety-driven is also not crazy. Anticipatory nausea is a documented phenomenon, particularly in people with emetophobia or health anxiety, and the two can compound each other.

What she got wrong, or at least imprecise, is calling the product "Wegovy tablet." Wegovy does not come in tablet form. This matters because viewers may go looking for a "Wegovy pill" based on this video and either find Rybelsus (wrong indication, different dosing) or unregulated compounded versions sold online. Neither of those outcomes is good. The label matters. Saying "oral semaglutide" or naming the specific product she's taking would be more accurate and less likely to send 117,000 viewers down a confusing path.

What should you actually know?

If you're starting any semaglutide product, a few things are worth knowing upfront. Nausea is common and tends to peak in the early weeks, especially around dose escalations. Staying hydrated matters more than usual because nausea reduces your drive to drink, which can lead to dehydration that makes nausea worse. It's a cycle. Eating smaller meals, avoiding high-fat foods, and not lying down right after eating are the standard behavioral recommendations for managing GLP-1-related nausea (Davies et al., 2021, Diabetes Care).

On the oral versus injectable question: bioavailability of oral semaglutide is genuinely lower and more variable than injectable forms. The OASIS 1 trial used 50mg oral doses to achieve effects comparable to the 2.4mg injectable. If someone hands you a low-dose oral semaglutide pill and tells you it works the same as Wegovy, that claim deserves serious skepticism. Compounded oral semaglutide products are not FDA-approved and have not been through the same efficacy and safety review process as brand-name drugs.

• Nausea affects up to 44% of semaglutide users in clinical trials
• Oral semaglutide requires much higher milligram doses due to poor gut absorption
• "Wegovy tablet" is not an FDA-approved product category as of 2024
• Anxiety around nausea can worsen perceived nausea symptoms independently

Bottom line

Allison seems like a genuine person documenting a real experience, and her transparency about anxiety and nausea is actually useful content. But the "Wegovy tablet" framing is a problem, not because she's lying, but because she may not fully understand what she's taking, and at 117K views, that imprecision spreads fast. If you're watching this and considering oral semaglutide, talk to a licensed prescriber about exactly which product you'd be getting and what the evidence actually supports for that specific formulation.